Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis.

Dysbiosis Gut Gut-liver axis Intestinal permeability Leaky gut Liver Microbiota

Journal

World journal of hepatology
ISSN: 1948-5182
Titre abrégé: World J Hepatol
Pays: United States
ID NLM: 101532469

Informations de publication

Date de publication:
27 May 2024
Historique:
received: 14 01 2024
revised: 12 02 2024
accepted: 12 04 2024
medline: 31 5 2024
pubmed: 31 5 2024
entrez: 31 5 2024
Statut: ppublish

Résumé

The gut-liver axis and bacterial translocation are important in cirrhosis, but there is no available universal biomarker of cellular bacterial translocation, for which presepsin may be a candidate. To evaluate the relationship of the blood presepsin levels with the state of the gut microbiota in cirrhosis in the absence of obvious infection. This study included 48 patients with Child-Pugh cirrhosis classes B and C and 15 healthy controls. The fecal microbiome was assessed using 16S rRNA gene sequencing. Plasma levels of presepsin were measured. A total of 22 patients received a probiotic ( Presepsin levels were higher in patients with cirrhosis than in healthy individuals [342 (91-2875) The level of presepsin directly correlates with the abundance in the gut microbiota of the main taxa that are substrates of bacterial translocation in cirrhosis. This biomarker, in the absence of obvious infection, seems important for assessing the state of the gut-liver axis in cirrhosis and deciding on therapy targeted at the gut microbiota in this disease.

Sections du résumé

BACKGROUND BACKGROUND
The gut-liver axis and bacterial translocation are important in cirrhosis, but there is no available universal biomarker of cellular bacterial translocation, for which presepsin may be a candidate.
AIM OBJECTIVE
To evaluate the relationship of the blood presepsin levels with the state of the gut microbiota in cirrhosis in the absence of obvious infection.
METHODS METHODS
This study included 48 patients with Child-Pugh cirrhosis classes B and C and 15 healthy controls. The fecal microbiome was assessed using 16S rRNA gene sequencing. Plasma levels of presepsin were measured. A total of 22 patients received a probiotic (
RESULTS RESULTS
Presepsin levels were higher in patients with cirrhosis than in healthy individuals [342 (91-2875)
CONCLUSION CONCLUSIONS
The level of presepsin directly correlates with the abundance in the gut microbiota of the main taxa that are substrates of bacterial translocation in cirrhosis. This biomarker, in the absence of obvious infection, seems important for assessing the state of the gut-liver axis in cirrhosis and deciding on therapy targeted at the gut microbiota in this disease.

Identifiants

pubmed: 38818295
doi: 10.4254/wjh.v16.i5.822
pmc: PMC11135270
doi:

Types de publication

Journal Article

Langues

eng

Pagination

822-831

Informations de copyright

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: No conflicts of interest.

Auteurs

Irina Efremova (I)

Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia.

Roman Maslennikov (R)

Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia.
Department of Scientific, Scientific Community for the Promotion of the Clinical Study of the Human Microbiome, Moscow 119435, Russia. mmmm00@yandex.ru.

Elena Poluektova (E)

Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia.
Department of Scientific, Scientific Community for the Promotion of the Clinical Study of the Human Microbiome, Moscow 119435, Russia.

Oleg Medvedev (O)

Department of Pharmacology, Lomonosov Moscow State University, Moscow 119192, Russia.

Anna Kudryavtseva (A)

Department of Post-Genomic Research Laboratory, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia.

George Krasnov (G)

Department of Post-Genomic Research Laboratory, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia.

Maria Fedorova (M)

Department of Post-Genomic Research Laboratory, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia.

Filipp Romanikhin (F)

Department of Pharmacology, Lomonosov Moscow State University, Moscow 119192, Russia.

Maria Zharkova (M)

Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia.

Oxana Zolnikova (O)

Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia.

Gyunay Bagieva (G)

Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia.

Vladimir Ivashkin (V)

Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia.
Department of Scientific, Scientific Community for the Promotion of the Clinical Study of the Human Microbiome, Moscow 119435, Russia.

Classifications MeSH